Pulmonary delivery for levodopa
View Patent ↗In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
1. A method of treating a patient with Parkinson's disease, that comprises:
administering to the respiratory tract of the patient particles that include about 90 weight percent levodopa or more, a salt wherein the salt is sodium chloride, and a phospholipid, wherein the particles are delivered to the pulmonary system.
2. A method of treating a patient with Parkinson's disease, that comprises:
administering to the respiratory tract of the patient particles that consist essentially of about 90 weight percent or more of levodopa an optional non-reducing sugar, a phospholipid, and a salt, wherein the salt is sodium chloride and wherein the particles are delivered to the pulmonary system and have a tap density less than about 0.4 g/cm 3 , a volume median geometric diameter greater than about 5 micrometers, and an aerodynamic diameter of from about 1 micrometer to about 5 micrometers.
3. The method of claim 2 , wherein the particles have an aerodynamic diameter of from about 1 micrometer to about 3 micrometers.
4. The method of claim 3 , wherein the particles have an aerodynamic diameter of from about 3 micrometer to about 5 micrometers.
5. The method of claim 3 , wherein the particles have a tap density less than about 0.3 g/cm 3 .
6. The method of claim 3 , wherein the particles have a tap density less than about 0.2 g/cm 3 .
7. The method of claim 3 , wherein the particles have a tap density less than about 0.1 g/cm 3 .
8. A method of treating a patient with Parkinson's disease, that comprises:
administering to the respiratory tract of the patient particles that include about 90 weight percent levodopa or more, a salt wherein the salt is sodium chloride and a phospholipid or a combination of phospholipids, wherein the particles are delivered to the pulmonary system.
9. The method of claim 8 , wherein the particles comprise 3% or less by weight of sodium chloride.
10. The method of claim 9 , wherein the phospholipid is dipalmitoyl phosphatidylcholine (DPPC).
11. A method of delivering an effective amount of L-Dopa to the pulmonary system, comprising:
providing a mass of particles comprising, by weight, about 90% or more L-Dopa, a salt wherein the salt is sodium chloride and about 10% or less DPPC; and administering via simultaneous dispersion and inhalation the particles, from a receptacle having the mass of the particles, to a human subject's respiratory tract.
12. The method of claim 11 , wherein the particles comprise, by weight, about 3% or less sodium chloride.
13. A method of treating a patient with Parkinson's disease, that comprises administering to the respiratory tract of the patient, particles that include about 90 weight percent levodopa or more and a salt, wherein the salt is sodium chloride and wherein the particles are delivered to the pulmonary system.
14. A method of treating Parkinson's disease in a patient in need thereof comprising:
administering to the respiratory tract of the patient, particles comprising levodopa, sodium chloride and dipalmitoyl phosphatidylcholine wherein the ratio of levodopa:DPPC:sodium chloride is about 90:8:2.